Stephen K. Brannan - 09 Jan 2023 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role
Chief Medical Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
09 Jan 2023
Net transactions value
-$954,029
Form type
4
Filing time
09 Jan 2023, 16:27:21 UTC
Previous filing
12 Dec 2022
Next filing
13 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $8,322 +1,527 +10% $5.45* 16,527 09 Jan 2023 Direct
transaction KRTX Common Stock Sale $301,613 -1,527 -9.2% $197.52 15,000 09 Jan 2023 Direct F1
transaction KRTX Common Stock Options Exercise $25,249 +3,473 +23% $7.27* 18,473 09 Jan 2023 Direct
transaction KRTX Common Stock Sale $685,987 -3,473 -19% $197.52 15,000 09 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -1,527 -4.2% $0.000000 34,677 09 Jan 2023 Common Stock 1,527 $5.45 Direct F2
transaction KRTX Option (right to buy) Options Exercise $0 -3,473 -100% $0.000000* 0 09 Jan 2023 Common Stock 3,473 $7.27 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2022.
F2 This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
F3 This option vested as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of August 8, 2018.